NCT03282513View on ClinicalTrials.gov

A Study of AG-120 (Ivosidenib) in Subjects With Mild or Moderate Hepatic Impairment or Normal Hepatic Function

PHASE1CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

September 26, 2017

Primary Completion Date

March 31, 2018

Study Completion Date

March 31, 2018

Conditions
Hepatic Impairment
Interventions
DRUG

AG-120 (Ivosidenib)

Single 500 mg dose of AG-120 (Ivosidenib).

Trial Locations (2)

55404

DaVita Clinical Research- Minnesota, Minneapolis

80228

DaVita Clinical Research- Colorado, Lakewood

Sponsors
All Listed Sponsors
lead

Agios Pharmaceuticals, Inc.

INDUSTRY